On this page
Published: April 1, 2026 · Last reviewed: May 1, 2026
Threat modeling for connected and implantable medical devices identifies assets, maps trust boundaries across every interface, enumerates threats (typically with STRIDE), and traces each threat to a mitigation and verification test. The FDA's Feb 3, 2026 premarket cybersecurity guidance treats it as a design-controlled activity, not a submission afterthought.
[Read the pillar guide] For the full step-by-step methodology, STRIDE application patterns, worked examples, and FDA reviewer expectations, see STRIDE Threat Modeling for Medical Devices. This post is a short orientation for teams new to the topic.
Why threat modeling matters for these devices
A missed attack vector on a hospital SaaS platform leads to a data breach. A missed attack vector on a networked insulin pump or an implantable cardiac device can directly harm a patient. That distinction shapes every decision in the process, from how you define scope to how you score and document risk.
The FDA's Feb 3, 2026 final premarket cybersecurity guidance makes threat modeling a required design activity for any cyber device under Section 524B of the FD&C Act. Reviewers expect to see a traceable model as a design input, not a document assembled retroactively before submission.
The five things reviewers look for
- System-wide scope. The model covers device, gateway, mobile app, cloud, clinician portal, and every network path between them, not just device firmware.
- Trust boundaries on the data flow diagram. Every boundary is analyzed against every STRIDE category. Partial coverage triggers Major deficiencies.
- Threats tied to harm. Each STRIDE entry connects to a clinical harm scenario per AAMI TIR57 / ANSI/AAMI SW96:2023 and ISO 14971, not just a generic CIA impact.
- Mitigation traceability. Each threat maps to a specific control, a verification test, and a residual risk entry in the security risk assessment.
- A living artifact. The model is version-controlled and updated with every architecture, firmware, or third-party component change, not frozen at submission.
Where to go next
The full methodology, including how to structure the data flow diagram, apply STRIDE without gaps, integrate with AAMI TIR57 / ANSI/AAMI SW96:2023 harm analysis, and produce the artifacts FDA reviewers expect, lives in the pillar guide:
- Pillar guide: STRIDE Threat Modeling for Medical Devices
- Related: Comparing DREAD, STRIDE, and PASTA Threat Models
- Related: FMEA vs Threat Modeling for Medical Devices
- Pillar: Medical Device Cybersecurity: 2026 Best Practices Guide — where threat modeling fits in the full lifecycle program
- Service: Threat Modeling Services
How Blue Goat Cyber approaches this
See also: TARA for Medical Devices: FDA Premarket, Data Flow Diagrams for Medical Device, and Brainjacking: The Real Cyber-Physical Threat to NeuroTech.
Blue Goat Cyber runs threat modeling end-to-end for connected and implantable device manufacturers, producing STRIDE registers, data flow diagrams with trust boundaries, and AAMI TIR57 / ANSI/AAMI SW96:2023 harm mappings that trace into the security risk assessment. Our team, credentialed across CISSP, OSCP, and ex-military red team backgrounds, delivers outputs structured for FDA review. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.
FAQ
Is STRIDE enough on its own for FDA submissions?
No. STRIDE gives you threat categorization, but the Feb 3, 2026 guidance also expects harm-based analysis per AAMI TIR57 / ANSI/AAMI SW96:2023 that ties each threat to a patient safety scenario. Pair the two so every STRIDE entry has a clinical harm and a mitigation traceable to a verification test.
When should threat modeling start?
At architecture definition, not at submission. Reviewers look for evidence that the model informed design decisions, so a model dated shortly before the 510(k) or PMA submission is a common trigger for Major deficiencies.
Do implantables need a different approach than connected devices?
The methodology is the same, but implantables add trust boundaries around the programmer, telemetry link, and any patient home monitor. Each of those boundaries needs full STRIDE coverage and a documented harm pathway.
Ready to build a submission-ready threat model?
If your team is preparing a premarket submission or responding to a cybersecurity deficiency, talk to Blue Goat Cyber about running threat modeling under our done-for-you model.
Reviewed July 13, 2026 by the Blue Goat Cyber team.